ProCE Banner Activity

CE / CME

Rheumatoid Arthritis: Key Updates on Guidelines, JAK Inhibitor Safety, and COVID-19 Considerations

PCE On Demand Live Presentation

Rheumatoid arthritis (RA) is a complex, fast-moving field that presents a number of challenges to NPs and PAs practicing in rheumatology. In this on-demand webcast, experts in RA review the numerous disease-modifying antirheumatic drugs (DMARDs) available and in development, the various combinations in which they can be used, the need to switch therapy for efficacy or safety reasons, and how DMARD therapy may need to be adjusted when patients are exposed to—or experience infection with—SARS-CoV-2.


In collaboration with the Society of Physician Assistants in Rheumatology

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit 0.1

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: October 10, 2022

Expiration: October 09, 2023

Begin Activity

Share

Faculty

Robin K. Dore

Robin K. Dore, MD

Clinical Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Shannon Ghizzoni

Shannon Ghizzoni, PA-C

Physician Assistant
Columbus Arthritis Center
Columbus, Ohio

Benjamin J. Smith

Benjamin J. Smith, DMSc, PA-C

Interim Program Director,
Associate Dean, Associate Professor
Florida State University College of Medicine
School of Physician Assistant Practice
Tallahassee, Florida
Rheumatology Physician Assistant
McIntosh Clinic, PC
Thomasville, Georgia

Acknowledgement

This activity is supported by an educational grant from Amgen.

Provided by

ProCE Banner

Target Audience

NPs and PAs specializing in rheumatology

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe key points from the American College of Rheumatology (ACR) 2021 RA guidelines

  • Utilize the latest data and recommendations for switching patients to another DMARD—or combination of DMARDs—if the current approach fails or leads to an inadequate response

  • Select patients who are the most appropriate candidates for Janus kinase inhibitor therapy and follow them for adverse events according to the latest data and guidelines

Disclosure

All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Robin Dore, MD: consultant/advisor/speaker fees: AbbVie, Amgen, Janssen, Lilly, Pfizer, Sanofi, UCB.

Shannon Ghizzoni, PA-C: consultant/advisor/speaker: AbbVie, Amgen, Novartis.

Benjamin J. Smith, DMSc, PA-C, has no relevant financial relationships to disclose.

Jennifer Simpson, DNP: consultant/advisor/speaker: Abbvie, Amgen, AstraZeneca, Horizon, Janssen.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose except Jennifer Simpson, DNP as noted above.

CME Info

Learners wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: October 10, 2022
Expiration date: October 9, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange, Partners for Advancing Clinical Education, or any educational supporter.

Accreditation

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Jennifer Simpson, DNP, Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 9, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.